Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K

Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types

Antoine M Snijders1, Jian-Hua Mao1

  • 1Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States.

Advances in Modern Oncology Research
|September 20, 2016
PubMed

Insights

Researchers identified 18 genes on chromosome 20q that are highly expressed in multiple cancers and linked to poor prognosis. Amplification drives this overexpression, suggesting these genes are potential targets for new cancer therapies.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Identifying effective molecular targets is crucial for advancing targeted cancer therapies.
  • Chromosome 20q amplifications are common in various human cancers, indicating the presence of multiple cancer-driving genes.

Purpose of the Study:

  • To identify potential molecular targets on chromosome 20q using a multi-omics approach.
  • To investigate the role of gene expression and copy number alterations in cancer development and prognosis.

Main Methods:

  • Comparative analysis of mRNA expression in 11 human cancer types versus normal tissues.
  • Utilized The Cancer Genome Atlas (TCGA) data for DNA copy number and gene expression.
  • Integrated multi-omics data to identify genes with elevated expression and copy number amplification.

Main Results:

  • Identified 18 genes with significantly elevated mRNA levels across multiple human cancers.
  • Found that high expression of these genes correlates with poor patient prognosis in many cancer types.
  • Determined that DNA copy number amplification is a primary driver of the overexpression of these 18 genes.

Conclusions:

  • The 18 identified genes on chromosome 20q represent potential novel molecular targets for targeted cancer therapy.
  • Understanding the mechanisms of gene amplification and overexpression on chromosome 20q can inform therapeutic strategies.
Keywords:
bioinformaticscancerchromosome 20qomicstherapeutic targets

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.3K